CRA consultants supported Endo International plc (Endo) in its successful challenge of products that infringed on its patents covering Opana® Extended Release (ER). Dr. Gregory K. Bell assessed the commercial success of Opana ER. He testified with respect to the issue of non-obviousness regarding the patents-in-suit, as the patents-in-suit enabled a long-lasting controlled release formulation of the painkiller. The District Court relied on secondary considerations of nonobviousness, including Dr. Bell’s testimony demonstrating the commercial success of Opana ER and the nexus of the patent claims and market success. Dr. Bell was supported by a team including Dr. Andrew Tepperman and Dr. Justin Ho.
An evidence-based framework to determine funding requirements for NCCPs
The report finds that NCCPs rarely specify the funds that need to be committed or the spending that occurs in practice. When evidence of funding impact is...